top stories

Thank­ful for nurs­es: J&J's new cam­paign aims to re­set pan­dem­ic clock back to grat­i­tude

2 days ago
Pharma
Marketing

Janet Wood­cock plots her fu­ture at FDA, with se­nior ad­vi­sor role to fall back on if Califf wins con­fir­ma­tion

2 days ago
FDA+

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

2 days ago
Marketing

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at ...

Yesterday
Weekly

Latest

Most read

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off ...

3 days ago
Pharma

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry ...

2 days ago
News Briefing
Cell/Gene Tx

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

2 days ago
R&D
FDA+

Drug­mak­ers cut prices on av­er­age by more than 60% to get on Chi­na's 2022 NDRL list — re­port

2 days ago
China
Pharma

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

2 days ago
Discovery
Coronavirus

Stoke touts ear­ly signs of ef­fi­ca­cy for Dravet syn­drome drug

2 days ago
R&D
see latest stream
People

In­mate who posed as Ab­b­Vie pur­chas­ing of­fi­cer in $3M scam sen­tenced to 7 more years of prison

3 days ago

Bob Nelsen woos John Maraganore to his first VC post af­ter re­tir­ing from Al­ny­lam

3 days ago

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

5 days ago
Financing

Ex-No­var­tis busi­ness head hops over to a gene ther­a­py start­up — and she's reeled in $80M for a dash to the clin­ic

3 days ago

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

3 days ago

Can the an­ti­body-drug con­ju­gate mod­el work for NK cells? Ace­po­dia loads up with an­oth­er $109M to find out

3 days ago
Startups

An­oth­er epigenome edit­ing start­up launch­es from a pair of the field’s long­time lead­ers

3 days ago

Look­ing to run with Big Phar­ma, a ra­dio­phar­ma start­up with back­ing from At­las, RA thinks it has the chops to com­pete

4 days ago

Af­ter Big Phar­ma sparked in­ter­est in the US, Ablaze looks to bring ra­dio­phar­ma­ceu­ti­cals over­seas

5 days ago
Deals

As­traZeneca nix­es $8B So­bi buy­out over fears a for­mer drug would be sold to ri­vals — re­port

2 days ago

A Seat­tle biotech of­floads lead eye drug in deal val­ued at $1B+ as it re­fo­cus­es on emerg­ing pipeline

3 days ago

Watch out, Roche: No­var­tis inks $1.5B deal to chase down promi­nent Parkin­son’s tar­get

3 days ago

Premium storiesSee all

Till­man Gern­gross on Omi­cron: 'It is a grim sit­u­a­tion...we’re go­ing to see a sig­nif­i­cant drop in vac­cine ef­fi­ca­cy'

6 days ago

Cures 2.0: Bi­par­ti­san House bill would al­low RWE to sat­is­fy con­fir­ma­to­ry tri­al re­quire­ments for ac­cel­er­at­ed ap­provals

3 weeks ago
FDA+

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

3 weeks ago
Cell/Gene Tx
In Focus

BioN­Tech CEO in­ter­view: On boost­ers, the fu­ture of Covid-19, and the plan to make and ship the next vac­cine in 3 ...

3 weeks ago
People
Coronavirus

Don't missSee all

Com­mon, Jamie Foxx among celebs stand­ing up for clin­i­cal tri­als in star-stud­ded can­cer group's pan­dem­ic push

3 days ago
Pharma
Marketing

A UK vac­cine cen­ter is on the mar­ket and field­ing of­fers from man­u­fac­tur­ing gi­ants

3 days ago
Manufacturing

British CD­MO Ster­ling part­ners up on low-cost man­u­fac­tur­ing of mol­nupi­ravir

3 days ago
Coronavirus
Manufacturing

Fu­ji­film Diosynth dumps an­oth­er $454M in­to its sup­ply chain, this time at a fa­cil­i­ty in the UK

3 days ago
Manufacturing

Endpoints Standouts

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

Last month
China
In Focus

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

2 months ago
Outsourcing
In Focus

The coro­n­avirus vac­cine that the world for­got could still help save it

2 months ago
Coronavirus
In Focus

In­side the quixot­ic 30-year quest that gave us the Covid-19 treat­ments, vac­cines and could un­lock vac­ci­nol­o­gy’s new ...

3 months ago
In Focus

Peer review See all

Dec
3

Joseph Ar­ron march­es to the beat of his own drum at 23andMe; Ex-Voy­ager CFO joins Sek Kathire­san at Verve ...

Nov
24

Tak­ing a leave of ab­sence, Am­pio Phar­ma­ceu­ti­cals CEO pass­es ba­ton to a new board mem­ber; Ax­el Hoos' can­cer biotech ...

Nov
19

Take­da on­col­o­gy vet drills down the 'ba­sic­s' at cell ther­a­py start­up; Sarep­ta pro­motes new R&D chief

Nov
12

Cy­toIm­mune CEO breaks down her 3 'pil­lars' of suc­cess; For­mer No­var­tis, Gilead ex­ec Alessan­dro Ri­va to lead an ul­tra ...

Nov
5

Pierre Beau­rang hits the ground run­ning at his 3rd start­up; Mike Grey poach­es Astel­las deal­mak­er to head pro­tein ...

Manufacturing channel feed

3 days ago

One work­er at a Lat­vian man­u­fac­tur­er is dead af­ter a fire breaks out at fa­cil­i­ty

A press re­lease re­ferred to it as sim­ply, “the in­ci­dent.” But a fire at an Olain­farm site in Latvia last week has left one per­son dead, and in­jured an­oth­er, the com­pa­ny an­nounced ...

READ MORE

Sam­sung Bi­o­log­ics takes on man­u­fac­tur­ing du­ties for Green­Light's Covid-19 vac­cine

3 days ago
Coronavirus

Covid-19 man­u­fac­tur­ing roundup: 3 com­pa­nies to col­lab­o­rate on mR­NA vac­cine; Omi­cron-fo­cused vac­cine could be on the ...

3 days ago
Coronavirus
latest in Manufacturing

More man­u­fac­tur­ing is­sues: Fen­nec preps for sec­ond CRL for po­ten­tial hear­ing loss drug

6 days ago
Pharma
FDA+

The deal for BeiGene's mas­sive new US man­u­fac­tur­ing and R&D site is com­plete, and it plans to pour in 'sev­er­al hun­dred mil­lion dol­lars' soon

Last week

UP­DAT­ED: The lat­est threat to the man­u­fac­tur­ing in­dus­try: sus­pi­cious mal­ware

Last week

At busy Visp site, Lon­za will up mi­cro­bial ser­vices by 50%

Last week

New drug ap­pli­ca­tions pile up with de­lays as there's no easy fix for the in­spec­tion back­log

Last week
see latest stories

Pharma channel feed

3 days ago

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

Af­ter South African sci­en­tists re­port­ed a new Covid-19 vari­ant — dubbed Omi­cron by the WHO — sci­en­tists be­came con­cerned about how ef­fec­tive vac­cines and mon­o­clon­al an­ti­bod­ies might be ...

READ MORE

UP­DAT­ED: Am­gen halts some drug dis­counts for safe­ty net hos­pi­tals as SCO­TUS takes on 340B case

3 days ago

What's fair? New ICER re­port shows pay­ers gen­er­al­ly en­sur­ing fair ac­cess to drugs

4 days ago
latest in Pharma

Glax­o­SmithK­line's friend­ly ‘shark tank’ crowd­sources ideas for mul­ti­ple myelo­ma, kicks off big­ger push

4 days ago
Marketing

Chi­na boasts 48% price cut on in­sulin as do­mes­tic drug­mak­ers eclipse Big Phar­ma in bulk or­der

4 days ago
China

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

5 days ago

Drug de­vel­op­ment 101: Gilead goes back to school with new pro­gram to at­tract Black and His­pan­ic stu­dents to phar­ma

5 days ago
Marketing

Mar­ket­ingRx roundup: Ab­b­Vie’s Hu­mi­ra TV turns fo­cus to HS skin con­di­tion; Sanofi amps par­ent­ing pol­i­cy

5 days ago
Marketing
see latest stories

R&D channel feed

3 days ago

With gener­ic com­pe­ti­tion heat­ing up, Vas Narasimhan out­lines No­var­tis' growth plans at R&D day

Thurs­day marks No­var­tis’ an­nu­al R&D day, and with it comes CEO Vas Narasimhan’s at­tempt to spot­light the com­pa­ny’s pipeline strat­e­gy and emerg­ing stars.

READ MORE

Bat­tling a line­up of skep­tics, Ver­tex claims an­oth­er ear­ly clin­i­cal win — this time in kid­ney dis­ease

4 days ago

VBI Vac­cines ex­ecs tout ap­proval of new triple-anti­gen he­pati­tis B shot. Can they sell it?

4 days ago
FDA+
latest in R&D

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

5 days ago
FDA+

How to use reg­istry da­ta to sup­port FDA de­ci­sion mak­ing: Agency ex­plains in new guid­ance

5 days ago
FDA+

UP­DAT­ED: Af­ter re­fut­ing a sup­posed da­ta leak as 'fal­si­fied', Ole­ma re­veals first clin­i­cal da­ta for lead pro­gram — shares crash

5 days ago

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

5 days ago

BD an­nounces an­oth­er ex­pan­sion, this time in San Diego

Last week
see latest stories

FDA+ channel feed

2 days ago

Ac­cel­er­at­ed ap­proval re­forms need mean­ing­ful con­fir­ma­to­ry tri­al im­prove­ments, pro­fes­sors write in Sci­ence

Out­side of Covid-19, 2021 has been the year of the ac­cel­er­at­ed ap­proval.

READ MORE

Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

4 days ago

J&J and Sanofi's mul­ti­ple myelo­ma tit-for-tat con­tin­ues, as sub­cu­ta­neous Darza­lex wins com­bo ap­proval

4 days ago
latest in FDA+

UP­DAT­ED: Stat­era Bio­phar­ma gets the OK to re­sume the study of a po­ten­tial stock­pile drug for lethal ra­di­a­tion ex­po­sure

4 days ago

FDA ad­comm nar­row­ly votes in fa­vor of Mer­ck­'s an­tivi­ral for out­pa­tient Covid-19

5 days ago
Coronavirus

UP­DAT­ED: FDA can­cels ODAC meet­ing this week as Se­cu­ra Bio pulls ac­cel­er­at­ed ap­proval

5 days ago

FDA rais­es con­cerns over TG Ther­a­peu­tic­s' sur­vival da­ta, plans to con­vene ODAC

5 days ago

Like the flu vac­cine every year, the FDA could move quick­ly on a vari­ant-tar­get­ed Covid vac­cine

6 days ago
Coronavirus
see latest stories